Table 2 Demographic characteristics of the CBS patients evaluated in the included studies; diagnostic criteria by which CBS patients were selected and the number of patients evaluated in the studies are also enlisted
References | Subgroups | Diagnostic criteria | Total patients, No | Age, mean (SD) | Women (No) | Age of onset, mean (SD) | MMSE score, mean (SD) | UPDRS-III, mean (SD) | H & Y, mean (SD) | Disease duration, mean (SD) | Country |
|---|---|---|---|---|---|---|---|---|---|---|---|
Olssonn et al. [31] | Â | Amstrong et al | 21 | 66 (7.6) | 12 | N | 16.9 (2.4) | N | N | N | Sweden |
Borroni et al. [37] | Â | Toronto Criteria | 16 | 61.3 (8.9) | 6 | 58.9 (9.7) | 25.2 (4.2) | 15.9 (9.5) | N | 1.73 (1.2) | Italy |
Magdalinou et al. [36] | Â | Cambridge Criteria | 14 | 69.8 (N) | 10 | N | N | N | 3.2 (N) | 3.5 (N) | UK |
Hansson et al. [27] | Lund cohort | Not defined | 5 | 69 (4.9) | 4 | N | 26.8 (2.9) | 38.4 (26.7) | 3.5 (1.7) | 3.6 (1.3) | Sweden |
London cohort | Toronto Criteria | 12 | 71 (7.2) | 9 | N | N | N | 3.2 (1.0) | 3.8 (2.2) | UK | |
Hall et al. [28] | Â | Amstrong et al | 6 | 67.8 (4.8) | 4 | N | 28.3 (2.9) | 8.8 (25.1) | 3.3 (1.7) | 3.3 (1.3) | Sweden |
Aerts et al. [15] | Â | Mayo Clinic Criteria | 12 | 69 (N) | 6 | N | 21.3 (6.8) | N | 2.5 (N) | 2 (N) | Netherlands |
Benvenutto et al. [33] | CBS-A+ | Amstrong et al | 14 | N | 6 | 64 (N) | 23 (N) | N | N | N | France |
CBS-A− |  | 16 | N | 8 | 65.5 (N) | 24 (N) | N | N | N | ||
Meeter et al. [24] | Â | Amstrong et al | 42 | 65 (N) | 14 | 62 (N) | N | N | N | 4 (N.) | Netherlands |
Alcolea et al. [[29] | Â | Amstrong et al | 21 | 72.6 (6.9) | 12 | N | 23.3 (6.7) | N | N | 4.6 (2.5) | Spain |
Borroni et al. [26] | CBS All | Amstrong et al | 30 | 63.5 (8.9) | 9 | 61 (9.3) | 23.6 (6.1) | 19.9 (11.5) | N | N | Italy |
CBS nAD-like | Â | 24 | 63.6 (9.8) | 8 | 60.9 (10.3) | 24.0 (6.2) | 22.7 (10.7) | N | N | ||
CBS AD-like | Â | 6 | 63.0 (4.0) | 1 | 61.6 (4.3) | 21.3 (5.8) | 7.2 (4.4) | N | N | ||
SPECT- nAD-like | Â | 18 | 62.2 (10.4) | 7 | 60.6 (11.0) | 25.1 (3.6) | 21.6 (10.5) | N | N | ||
SPECT- AD-like | Â | 5 | 63.6 (4.2) | 0 | 62.6 (4.6) | 23.0 (4.6) | 6.7 (5.0) | N | N | ||
Constantinides et al. [52] | Â | Amstrong et al | 5 | N | N | N | N | N | N | N | Greece |
Luk et al. [35] | Cohort A | Not defined | 5 | 73 (5.95) | N | N | N | N | N | N | Spain |
Cohort B | Â | 4 | 69.5 (8.8) | N | N | N | N | N | N | Germany | |
Cohort C | Â | 8 | 72.6 (6.7) | N | N | N | N | N | N | Sweden | |
Cohort D | Â | 5 | 59.23 (11.2) | N | N | N | N | N | N | Netherlands | |
All cohorts | Â | 22 | 69.6 (8.6) | N | N | N | N | N | N | ||
Cohort A + D |  | 10 | N. (N.) | N | N | N | N | N | N | ||
Boman et al. [22] | CBS + PSP patients | Amstrong et al | 11 | 71 (N) | 4 | N | N | N | N | 3 (N) | Sweden |
Jabbari et al. [34] | CBS All | Amstrong et al | 40 | 68.4 (7.4) | 26 | 63.6 (7.2) | N | N | N | N | UK |
Unknown pathology | Â | 23 | 68.3 (6.8) | 16 | 63.9 (7.6) | N | N | N | N | ||
4RT | Â | 9 | 67.5 (8.6) | 5 | 61.8 (9.6) | N | N | N | N | ||
AD | Â | 8 | 69.7 (8.3) | 5 | 64.6 (7.6) | N | N | N | N | ||
Delaby et al. [25] | Â | Not defined | 26 | 72 (7.3) | 13 | N | 22.5 (5.3) | N | N | N | Spain |
Doss et al. [23] | CBS + PSP patients | Not defined | 11 | N | N | N | N | N | N | N | Germany |
Quadalti et al. [20] | CBS + PSP patients | Amstrong et al | 58 | 71.2 (6.8) | 27 | N | 25.1 (5.4) | 38.9 (25.4) | 2.7 (0.8) | N | Italy |
Rodriguez et al. [52] | CBS + PSP patients | Amstrong et al | 11 | 71.2 (N) | 8 | N | 23.1 (6.7) | N | N | N | Spain |
Bjorkhem et al. [32] | Â | Amstrong et al | 11 | 68.9 (5.4) | 4 | N | N | N | N | 2.5 (1.7) | USA |
Schulz et al. [30] | Â | Amstrong et al | 16 | 69.25 (5.6) | 8 | N | 21.18 (6.10) | N | N | N | Germany |
Di Stefano F et al. [51] | CBS | Modified Cambridge Criteria | 45 | 69.2 (7.5) | 22 | 65.9 (7.4) | 21.5 (6.5) | N | N | 3.2 (1.8) | France |
CBS AD +  |  | 8 | 66.25 (7.8) | 3 | N | 21.25 (4.5) | N | N | 3.87 (2.29) | ||
CBS AD - | Â | 37 | 65.83 (7.4) | 19 | N | 21.52 (6.8) | N | N | 3.16 (1.7) |